If they do not want to be randomised, or if they have a preference or dislike for one specific treatment, they do not want to be included in the study.
Or, they might agree to be randomised but suffer from 'resentful demoralisation' if they end up in the non-preferred arm of the trial, leading to poor adherence.
If patients are randomised to no surgery they are subsequently randomised to carboplatin and paclitaxel or carboplatin/paclitaxel and bevacizumab.
All prospective, randomised controlled clinical trials (RCTs) were included if they were randomised studies of BV injections at acupoints as the sole treatment, or as an adjunct to other treatments if the control group received the same treatment as the BVA group.
For example, if patients are randomised and then are assigned to a therapist, therapist would be considered post-randomisation clustering.
All screened patients were randomised, and complete follow-up was achieved for all randomised patients.
Study selection: Studies were included if they were randomised comparisons of loop or thiazide diuretics and control, or one diuretic and another active agent (e.g. ACE inhibitors, ibopamine and digoxin).
Studies were included if they were randomised trials of a structured exercise intervention (versus usual care) for participants with coronary heart disease and reported at least one of cardiovascular mortality, total mortality, myocardial infarction or revascularisation outcomes.
Studies were eligible if they were randomised controlled trials with at least one arm that compared exercise-based cardiac rehabilitation to usual care, and which reported at least one of the following outcomes: total mortality, cardiovascular mortality, myocardial infarction, coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI).
